Friday, October 30, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleSeeking Alpha· July 29, 2026

Landstar outlines July truck revenue per load up about 26% year-over-year while shifting to Q3 commentary over guidance

View original at seekingalpha.com
“we ended the quarter with cash and short-term investments of $348 million”
Verbatim excerpt from the source · Seeking Alpha · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Whether insurance pricing resets later is uncertain given time until renewal.

    60% confidence
  • Landstar added a net 49 trucks in the most recent 4-week period of July, with quarterly turnover at 28.3%.

    60% confidence
  • July 2026 truck loads were approximately 5% above July 2025.

    60% confidence
  • Scale will continue to matter for Landstar amid rising claims costs.

    60% confidence
  • Landstar welcomed an $18 million freight broker from the Midwest to its agent network.

    60% confidence
  • Minimum federal carrier selection standards would be important for the industry.

    60% confidence
  • SG&A costs were $68.2 million in Q2 2026 versus $55.7 million in Q2 2025, including incentive comp of $6.4 million versus $1 million.

    60% confidence
  • Insurance and claims costs were $39.4 million in Q2 2026 versus $30.4 million in Q2 2025, including a $10.5 million net unfavorable prior-year claims adjustment.

    60% confidence
  • Broker liability insurance renewal pricing was up 3%.

    60% confidence
  • The data center pipeline is looking very strong.

    60% confidence
  • Landstar is not averse to M&A but prefers finding more $18 million agents.

    60% confidence
  • A carrier having an accident does not automatically make Landstar liable.

    60% confidence
  • Pleased with revenue and variable contribution performance in Q2 2026 despite a challenging insurance/claims quarter.

    60% confidence
  • Variable contribution was $199.4 million in Q2 2026 versus $170.5 million in Q2 2025.

    60% confidence
  • Carrier count reduction efforts started with addressing cargo fraud.

    60% confidence
  • Pricing was nearly 400 basis points better than normal in May and June, and about 150 basis points better than normal in July.

    60% confidence
  • Sequential truck revenue per load increased 14.4%, the largest sequential increase in 15 years.

    60% confidence
  • Landstar will provide Q3 commentary rather than formal guidance due to a fluid freight backdrop and volatile litigation/claims environment.

    60% confidence
  • Revenue grew 18% year-over-year in Q2 2026.

    60% confidence
  • Landstar renewed its insurance tower for the next 12 months effective June 1, 2026.

    60% confidence
  • No meaningful adjustments were needed to insurance endorsements or deductibles.

    60% confidence
  • Gross profit was $132.3 million in Q2 2026 versus $109.3 million in Q2 2025.

    60% confidence
  • An AI rollout plan to agent offices begins mid-Q3 2026.

    60% confidence
  • Brokerage losses have historically been less than 20 basis points of gross brokerage revenue.

    60% confidence
  • No meaningful change in broker-liability claims backlog since the Montgomery decision.

    60% confidence
  • LTL declines are agent-specific rather than systemic.

    60% confidence
  • Utilization was up 12% year-over-year.

    60% confidence
  • July 2026 revenue per load was approximately 26% above July 2025.

    60% confidence
  • Brokerage volumes were negative because BCOs are more active, leaving less freight to lay off to third-party carriers.

    60% confidence
  • Three claims driving the reserve adds previously had zero reserves.

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com